Latest News for: skye

Edit

Failure to Satisfy Listing Rule (Form 8-K) (Skye Bioscience Inc)

Public Technologies 15 May 2026
On May 13, 2026, Skye Bioscience, Inc. (the "Company" or "Skye") received a written notification from the Listing Qualifications Department of The Nasdaq Stock ... Skye Bioscience Inc.
Edit

Initial Quarterly Holdings Report by Institutional Manager (Form 13F-HR) (Skye Global Management LP)

Public Technologies 15 May 2026
) ... The reader should not assume that the information is accurate and complete ... Washington, D.C ... Skye Global Management LP ... 0 ... Skye Global Management LP published this content on May 15, 2026, and is solely responsible for the information contained herein.
Edit

Court Decides Former Skye Bank Chairman, Ayeni’s Bail Request May 25

This Day 14 May 2026
Justice Jude Onwuzuruike of a High Court of the Federal Capital Territory (FCT) in Apo, Abuja, will on May 25, decide whether to grant bail to a former Chairman of the Board of Directors of Skye Bank Plc, Tunde Ayeni, in his alleged corruption trial.
Edit

Agriculture employees sue Rollins over ‘escalating’ religious messaging

Federal News Radio 14 May 2026
The , filed in the U.S ... “We work for the federal government, not a church ... Register today! ... Read more. Litigation ... “The government is not permitted to force religion on people in this country,” said Skye Perryman, president and CEO of Democracy Forward ... .
Edit

Corporate Presentation (260511 Skye Corporate Presentation) (Skye Bioscience Inc)

Public Technologies 12 May 2026
). The text version of this document is not available ... Skye Bioscience Inc.
Edit

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Nasdaq Globe Newswire 12 May 2026
SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing ...
Edit

Corporate Presentation View Presentation ( 260511 Skye Corporate Presentation ) (Skye Bioscience Inc)

Public Technologies 12 May 2026
SKYE ... © 2026 Skye Bioscience, Inc ... Skye has developed a combination strategy for nimacimab + semaglutide that has the potential to provide a compelling new therapeutic option for patients ... © 2026 Skye Bioscience, Inc ... © 2026 Skye Bioscience, Inc.
Edit

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (Skye Bioscience Inc)

Public Technologies 12 May 2026
SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, ...
Edit

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (Skye Bioscience Inc)

Public Technologies 12 May 2026
SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, ...
Edit

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Nasdaq Globe Newswire 11 May 2026
SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related ...
Edit

Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) (Skye Bioscience Inc)

Public Technologies 11 May 2026
Skye Bioscience, Inc." and "--Financial Overview - Estimated Legal Contingency"; and ... Skye Bioscience Inc.
×